Drug
Trifluridine clinical trials
- studies test it
- 10
- open now
- 3
- in phase 3
- 2
- first study started
- 2013
Keep track of what changes. Save the Trifluridine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
8 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2022 | 1 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 2
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Centre Georges Francois Leclerc (1) · Taiho Oncology, Inc. (1) · Institut de Recherches Internationales Servier (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Amgen (1) · Sun Yat-sen University (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Tipiracil (7) · Bevacizumab (2) · Bemarituzumab (1) · Paclitaxel (1) · Ramucirumab (1) · Irinotecan (1) · Vilamakitug (1) · Trifluridine tipiracil drug combination (1)
Studies
Open first, then newest update. How each study uses Trifluridine is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07361003Written as Suvemcitug injection, trifluridine/tipiracil tablets
- Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07261709Written as Trifluridine/tipiracil plus fruquintinib
- Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06992648Written as Trifluridine/Tipiracil + Regorafenib
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerSuspendedPhase 2M.D. Anderson Cancer CenterNCT07011550Written as Trifluridine + Tipiracil
- Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06680622Written as bemarituzumab, trifluridine/tipiracil
- Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, FluoropyrimidineActive, not recruitingPhase 1/2Centre Georges Francois LeclercNCT05201352Written as trifluridine/tipiracil + XB2001
- Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD AloneCompletedPhase 1Taiho Oncology, Inc.NCT01867866Written as Trifluridine
- A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive TherapyCompletedPhase 2Institut de Recherches Internationales ServierNCT02743221Written as Trifluridine/tipiracil + bevacizumab
- Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical TrifluridineCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00000635Written as Trifluridine
- Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot StudyCompletedNot applicableAmgenNCT00002037Written as Trifluridine
Given in every arm · 2 — Trifluridine is usual care beside what is tested
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasRecruitingPhase 1Inhibrx Biosciences, IncNCT03715933Written as Trifluridine + Tipiracil
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsTerminatedPhase 1Astellas Pharma Global Development, Inc.NCT05083481Written as Trifluridine + Tipiracil
As the comparator · 1 — what is tested is compared with Trifluridine
Codes
What other systems call Trifluridine · ClinicalTrials.gg INT008356
- MeSH (NLM) D014271TrifluridineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) RMW9V5RW38TRIFLURIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 10803Confirmed FDA, Wikidata
- Wikidata Q2359590trifluridineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C905TrifluridineOne source FDA
- DrugBank DB00432One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D014271 | Trifluridine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | RMW9V5RW38 | TRIFLURIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 10803 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2359590 | trifluridine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C905 | Trifluridine | One source FDA |
| DrugBank | DB00432 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.